<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20030606150215</creation_date><modification_date>D:20030606150220+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-01-178_h_dec_3.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communitiesbrussels, 04/06/2003c(2003) 1843
 not for publication</p></section><section><header>commission decisionof 04/06/2003
 amending decision c(2001)818 on the marketing authorization for
 the medicinal product for human use
 &quot;targretin - bexarotene&quot;
 (text with eea relevance)</header><p>only the english text is authentic.</p></section><section><header>commission decisionof 04/06/2003
 amending decision c(2001)818 on the marketing authorization for
 the medicinal product for human use
 &quot;targretin - bexarotene&quot;
 (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and inparticular article 10(2) thereof,
 having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;targretin - bexarotene&quot; entered in the community
 register of medicinal products under nos eu/1/01/178/001 authorised by
 commission decision c(2001)818 of 29 march 2001, as amended, complies with
 the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>ligand pharmaceuticals uk ltd submitted an application to change the package
 leaflet on 23 april 2003 pursuant to article 61(3) of directive 2001/83/ec
 3.(3)</p><p>the proposed changes are not connected with the contents of the summary of
 characteristics of the medicinal product in question.
 (4)</p><p>the package leaflet as changed continues to comply with title v of directive
 2001/83/ec
 (5)</p><p>decision c(2001)818 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj l 311, 28.11.2001, p. 67.has adopted this decision:article 1decision c(2001)818 is amended as follows:a) annex iii b is replaced by the annex to this decision.
 article 2this decision is addressed to ligand pharmaceuticals uk ltd, innovis house, 108 highstreet, crawley, west sussex rh10 1bb, united kingdom.
 done at brussels, 04/06/2003
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>